Vasculitis Expert Receives the Vaccine Dr. Carol Langford, Director of the Cleveland Clinic Center for Vasculitis Care and Research, received her first dose of a Covid-19 vaccine on New Year’s Eve. Dr. Langford is recognized worldwide for her clinical care and research in the field of vasculitis. Dr. Langford studies…...
Recruiting: Efficacy and Safety of Benralizumab in EGPA compared to Mepolizumab (MANDARA)
Brief Summary: This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive…...
Leading Vasculitis Physician-Scientist Receives Covid-19 Vaccine
Dr. Peter Merkel, Director of the University of Pennsylvania Vasculitis Center and Co-Principal Investigator of the Vasculitis Patient-Powered Research Network, received his first dose of a COVID-19 vaccine just before New Year’s Eve. Dr. Merkel says “I am excited that the vaccine will become increasingly available to everyone, especially patients…...
